Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Catalent Inc (CTLT)

Catalent Inc (CTLT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,966,568
  • Shares Outstanding, K 180,980
  • Annual Sales, $ 4,263 M
  • Annual Income, $ -256,000 K
  • 60-Month Beta 1.20
  • Price/Sales 2.34
  • Price/Cash Flow 17.10
  • Price/Book 2.78
Trade CTLT with:

Options Overview Details

View History
  • Implied Volatility 24.83% ( -1.82%)
  • Historical Volatility 10.01%
  • IV Percentile 27%
  • IV Rank 24.62%
  • IV High 67.32% on 02/02/24
  • IV Low 10.94% on 05/24/24
  • Put/Call Vol Ratio 0.90
  • Today's Volume 1,125
  • Volume Avg (30-Day) 1,947
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 57,658
  • Open Int (30-Day) 38,220

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.55
  • Number of Estimates 4
  • High Estimate 0.58
  • Low Estimate 0.52
  • Prior Year 0.09
  • Growth Rate Est. (year over year) +511.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.51 +2.92%
on 05/29/24
56.54 -2.60%
on 06/07/24
-0.30 (-0.54%)
since 05/17/24
3-Month
53.51 +2.92%
on 05/29/24
57.20 -3.72%
on 04/11/24
-0.89 (-1.59%)
since 03/18/24
52-Week
31.80 +73.18%
on 11/01/23
60.20 -8.52%
on 02/05/24
+10.96 (+24.85%)
since 06/16/23

Most Recent Stories

More News
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?

Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights.

NVO : 140.80 (+0.31%)
BMO : 84.16 (+0.44%)
CTLT : 55.07 (-0.25%)
HIMS : 24.79 (+2.65%)
LLY : 891.46 (+0.73%)
Catalent: Fiscal Q3 Earnings Snapshot

Catalent: Fiscal Q3 Earnings Snapshot

CTLT : 55.07 (-0.25%)
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?

All three of these high-flying stocks could have more room to run.

CTLT : 55.07 (-0.25%)
NVO : 140.80 (+0.31%)
LLY : 891.46 (+0.73%)
VKTX : 50.64 (-2.65%)
Did Novo Nordisk Just Get a Jump on Eli Lilly?

A recent FDA announcement may have just put one company in the lead.

LLY : 891.46 (+0.73%)
CTLT : 55.07 (-0.25%)
NVO : 140.80 (+0.31%)
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why

Eli Lilly and Novo Nordisk dominate the diabetes market thanks to blockbuster medications Mounjaro, Ozempic, and Rybelsus.

CTLT : 55.07 (-0.25%)
LLY : 891.46 (+0.73%)
NVO : 140.80 (+0.31%)
Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's...

CTLT : 55.07 (-0.25%)
LVMUY : 152.4600 (-1.70%)
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?

Even more revenue is on the way from additional sales of Wegovy.

LLY : 891.46 (+0.73%)
CTLT : 55.07 (-0.25%)
NVO : 140.80 (+0.31%)
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited

Novo Nordisk just made a unique acquisition to help bolster the supply of Wegovy and Ozempic.

CTLT : 55.07 (-0.25%)
NVO : 140.80 (+0.31%)
Catalent: Fiscal Q2 Earnings Snapshot

Catalent: Fiscal Q2 Earnings Snapshot

CTLT : 55.07 (-0.25%)
Novo Nordisk vs. Eli Lilly: Which Mega-Cap Healthcare Stock is a Better Buy for 2024?

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

NVO : 140.80 (+0.31%)
LLY : 891.46 (+0.73%)
CTLT : 55.07 (-0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Catalent, Inc. is a renowned global provider of advanced delivery technologies as well as development and manufacturing solutions for drugs (protein, cell, and gene therapy biologics) and consumer health products.

See More

Key Turning Points

3rd Resistance Point 55.51
2nd Resistance Point 55.40
1st Resistance Point 55.24
Last Price 55.07
1st Support Level 54.97
2nd Support Level 54.86
3rd Support Level 54.70

See More

52-Week High 60.20
Last Price 55.07
Fibonacci 61.8% 49.35
Fibonacci 50% 46.00
Fibonacci 38.2% 42.65
52-Week Low 31.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar